Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273210 | 0.83 | TBXA2R (0.44) | NPC1RAB9ATBXA2RLMNASMN1; SMN2 | |
| SCHEMBL10273211 | 0.83 | LMNA (0.40) | NPC1RAB9ATBXA2RLMNASMN1; SMN2 | |
| SCHEMBL10273812 | 0.82 | KCNH2 (0.40) | NPC1RAB9APKMTBXA2RLMNA | |
| SCHEMBL16172555 | 0.81 | TBXA2R (0.42) | CYP3A4NPC1RAB9ATBXA2RLMNA | |
| SCHEMBL10272861 | 0.81 | TBXA2R (0.42) | CYP3A4NPC1RAB9ATBXA2RLMNA | |
| SCHEMBL10272867 | 0.79 | SMN1; SMN2 (0.47) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10273213 | 0.75 | LMNA (0.39) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10273207 | 0.74 | SMN1; SMN2 (0.38) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10273021 | 0.74 | TBXA2R (0.40) | TBXA2RTBXAS1 | |
| SCHEMBL16172553 | 0.72 | LMNA (0.36) | NPC1RAB9ALMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | CYP3A4 1863/4885HTR7 4024/4885NPC1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.